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To study association between HI.A-DRB1*01 and HLA-DRBI*IS
with ulcerative colitis in Kerman
Background and Objective:
Inflammatory bowel disease (BD) is one of the autoimmune diseases with the unknown crilrse.
The disease includes ulcerdive colitis and Crohn's disease. Genetic and environmental factors
can be possible cause of IBD. The human Major Histocompatibility Complex G\e{C) is located
between 6p2l.l and 6p21.3 and it is one of the genetic factors which correlated with ulcerative
colitis. There are several evidences on the association of ulcerative colitis and HLA class fI gene
polymorphisms, particularly HLA-DRBI. The purpose of this study is investigation of the
association between HLA-DRBI particularly DRBI*0l and DRBI*I5 with ulcerative colitis in
Kerman.
Methods:
180 subject including 95 healthy contols and 85 patients with ulcerative colitis disease enrolled
in our study. DNA was exhacted from the whole blood and molecular technique based on PCR-
SSP were employed to detect HLA-DRBI*0I and HLA-DRBI+I5.
Results:
85 patients (malr39, fernalr46) with mean age of 37.3gt1.76 and 95 healthy controls
(malr43, femalr52) with mean age of 37.13+L.2 were HLA qlped and the allelic @uency for
DRBI+OI and DRB*15 was 13.9% and26.8Yo respectively. No significant difference was found
betrueen the cases and the controls with regard to the frequency of DRBI*OI and DRBI+I5.
However, the allelic frequency of HLA DRBI*04 was significantly higher in controls thm
patients (p value:A.B). Additionally, the highest @uency of HLA-DRBI alleles in our
population was belonged to HLA-DRBI*Il (307o), DRBI*I5 Q6.8Y.) and DRB1*|3 Q4.4W
respectively whereas the lowest @uency was reported for DRBI+|2 and DRBI*O9 (l.l@-
Frequency of DRBI*01:01 (10.1fflo) as a subgroup of DRBI*OI and DRBI*15:01 (6.70/o) as t
subgroup of DRBI+I5 were higher than other alleles. Additionally, no association was fomd
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between @ue,ncy of HLA-DRBI and gender in our patients and in the whole population (cases
and controls). On the other hand we could not find any association between ES& CRP, blood in
stool and [Ib level with inheritance of HLA-DRBI in ulcertive colitis patients. Howwer, bowel
movements and severity of disease in UC patients were associated with DRBI+0101 and
DRB I + I 3, respectively Qt vahrc:0.01).
Conclusion:
Taken togetheq we could not find any association between DRBI*OI and HLA-DRBI*I5 with
ulcerative colitis in our populdion which is similar to the genetic analysis from England and
Korea On the other hand, HLA-DRBI*O4 in our populdion may have protective role against
ulcerative colitis which is in concordance with genetic results from UC patients in England.
There are discrepancy between our results and results of UC patients from Netherlands, US and
Turkey. Additionally, our results showed the highest @uency for DRBI+Il, DRBI+IS and
DRB1*13 whereas the lowest frequency was belong to DRBI*(D and DRB1+12 in our
population which was in agree with other studies from han, Asia md Europe and disagree with
some results from Mexico and Middle East. Differences involving races and populations might
explain inconsiste,ncies between our results and the other genetic shrdies. Interestingly, our results
showed association between DRBl*0101 allele and bowel movements. Additionally, DRBI*13
was correlated with severity of disease in our patients. To our knowledge, this is the frst report
showing the pathological symptoms such as bowel movement and severity of disease in
ulcerative colitis patients are related to DRB1*0101 allele and DRBI*l3 which might be a
valuable prediction tools for better diagnosis of UC.
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